‘The pharmaceutical industry is looking to occupy the KRW 15 billion neutropenia treatment market’

The neutropenia treatment market, expected to form a KRW 15 billion market for the first time and grow significantly every year, will get into a competing structure.

It is known that the top pharmaceutical companies with their own cutting-edge technologies and economic prices will enter the market, formed exclusively by the Kyowa Hakko Kirin Korea’s ‘Neulasta’.

This is the market that the Kyo...